The Rockefeller University

The Rockefeller University

The Rockefeller University

Date Founded




Charitable Causes

Higher Education & Universities
Education Research & Support

Employees (Worldwide)



Social Interest
Investment Services & Portfolio Management
Schools & Student Services

Company Description

The Rockefeller University (the University) is a world renowned center for research (see schedule O) and graduate education in the biomedical sciences, chemistry, bioinformatics, and physics. The University's 82 laboratories conduct both clinical and basic research and study a diverse range of biological and biomedical problems with the mission of improving the understanding of life for the benefit of humanity. Laboratories are loosely clustered in nine research areas covering a wide spectrum of disciplines in the life sciences, including neuroscience, immunology, genetics, structural biology and bioinformatics. The University does not charge tuition. Its revenues are derived primarily from investment income, government grants and contracts, and private gifts and grants.

Contact Data
Trying to get in touch with decision makers at The Rockefeller University? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees


Vice President & Chief Investment Officer

Vice President & General Counsel

Zachary & Elizabeth M. Fisher Professor in Alzheimer's & Neurodegenerative Disease Vice President for Educational Affairs Dean of Graduate & Postgraduate Studies, Head, Patricia & John Rosenwa

Richard M. & Isabel P. Furlaud Professor Senior Physician, Head, Laboratory of Chemical Biology & Signal Transduction

Richard & Jeanne Fisher Professor Vice President for Academic Affairs, Head, Laboratory of Genetics

Theresa & Eugene M. Lang Professor, Head, Leonard Wagner Laboratory of Molecular Genetics & Immunology

Professor, Head of Laborat

Pels Family Professor, Head, Selma & Lawrence Ruben Laboratory of Chemistry & Cell Biology

Richard E. Salomon Family Professor, Head, Laboratory of Developmental Genetics

Board of Directors

Chairman of the Board & Chief Executive Officer at Royalty Pharma Plc

Paths to The Rockefeller University
Potential Connections via
Relationship Science
The Rockefeller University
Advisors & Consultants
Legal Advisor

Foley & Lardner LLP provide legal services. It provides corporate governance, compliance, securities, mergers and acquisitions, litigation, labor, employment, intellectual property, IP litigation and tax services. The firm has offices in Boston, Brussels, Chicago, Detroit, Jacksonville, Los Angeles, New York, Orlando, Sacramento, San Diego, Del Mar, San Francisco, Silicon Valley, Tallahassee, Tampa, Tokyo, Washington, D.C. and West Palm Beach. The company was founded in 1842 and is headquartered in Milwaukee, WI.

Legal Advisor

Shareholder at Greenberg Traurig LLP


Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. In 25 years, Gilead has become a leading biopharmaceutical company with a portfolio of 15 marketed products, a growing pipeline of investigational drugs and approximately 5,000 employees in offices across four continents. Gilead's therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation

Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. These innovative tools enable us to develop complex generics and follow-on biologics as well as facilitate the discovery of novel drugs. We believe that by applying our innovative technology to our discovery and development programs, we have the potential to create a robust pipeline of innovative generic and novel drugs. Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs. In July 2010, Momenta announced the FDA approval of our first drug, enoxaparin sodium injection developed in collaboration with Sandoz. Enoxaparin is a more affordable, generic version of Lovenox® (enoxaparin sodium injection), which is indicated for the prophylaxis of deep vein thrombosis (DVT). Enoxaparin sodium injection is a heparin-based complex mixture drug that was developed using our innovative scientific approach. Following this initial success, we are applying a similar approach to developing a generic version of Copaxone® (glatiramer acetate), a complex mixture of polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis. We are also adding follow-on biologics, which are highly similar and potentially interchangeable biologics, to our development pipeline. And finally, with the knowledge acquired from our complex generic and follow-on biologics business, we are our using our tools and technology to design and improve the structures of proteins and heparin-derived products to create novel drugs

Key Stats and Financials As of 2019
Market Capitalization
Total Enterprise Value
Earnings Per Share
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
Details Hidden

Virdante Pharmaceuticals, Inc. develops and commercializes drugs for auto-immune and inflammatory disorders. The company's products incorporate a proprietary 'sialic switch' technology to improve the anti-inflammatory properties of antibodies. It was founded in 2008 and is headquartered in Cambridge, MA.

Celldex Therapeutics Inc. Pension Funds & Sovereign Wealth | Hampton, NJ

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Turner Construction Company Engineering, Construction & Architecture | New York, NY

Turner Construction Co. provides construction and general contracting services. Its services include preconstruction consulting, program management, general construction, project and construction management, building maintenance and multiple building programs. The company was founded in 1902 and is headquartered in New York, NY.

Rafael Vinoly Architects PC Pension Funds & Sovereign Wealth

Rafael Viñoly Architects is a critically acclaimed international practice headquartered in New York, with offices in London, Los Angeles.

Awards & Honors
Rank #226
The Chronicle of Philanthropy - Philanthropy 400
Rank #267
The Chronicle of Philanthropy - Philanthropy 400
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by The Rockefeller University. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of The Rockefeller University's profile does not indicate a business or promotional relationship of any kind between RelSci and The Rockefeller University.